Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: SMC Global Securities Limited
$23.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Lupin Ltd's Subsidiary Receives FDA Approval For Generic Rifadin Capsules


Friday, 23 Aug 2013 06:26am EDT 

Lupin Limited announced that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received final approval for its Rifampin Capsules USP, 150 mg and 300 mg strengths from the United States Food and Drugs Administration (FDA). 

Company Quote

1285.4
-4.25 -0.33%
28 Aug 2014